Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou, Simon Peter Gampenrieder (Co-author), Sophie Frantal, Gabriel Rinnerthaler (Co-author), Christian F Singer, Daniel Egle, Georg Pfeiler, Rupert Bartsch, Viktor Wette, Angelika Pichler, Edgar Petru, Peter C Dubsky, Zsuzsanna Bago-Horvath, Christian Fesl, Margaretha Rudas, Anders Ståhlberg, Ricarda Graf, Sabrina Weber, Nadia Dandachi, Martin FilipitsMichael Gnant, Marija Balic, Ellen Heitzer

Research output: Contribution to journalOriginal Articlepeer-review

29 Citations (Web of Science)
Original languageEnglish
Pages (from-to)697-707
JournalCLINICAL CANCER RESEARCH
Volume28
Issue number4
DOIs
Publication statusPublished - 2022

Keywords

  • INFILTRATING LYMPHOCYTES
  • LIQUID BIOPSY
  • THERAPY
  • BURDEN
  • DNA
  • CHEMOTHERAPY
  • RISK

Cite this